[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Morris M, Platell C, Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res; 2008 Mar 1;14(5):1413-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
  • The aim of the present study was to investigate the prognostic significance of TILs and other routinely reported pathologic features in colon cancer, particularly in relation to the use of adjuvant chemotherapy.
  • EXPERIMENTAL DESIGN: Pathologic markers, disease-specific survival, and the use of adjuvant chemotherapy were recorded in a retrospective, population-based series of 1,156 stage III colon cancer patients with a median follow-up time of 52 months.
  • In patients treated with 5-fluorouracil-based chemotherapy (n = 305), TILs were associated with significantly improved survival [hazard ratio (HR), 0.52; 95% confidence interval, 0.30-0.91; P = 0.02] and perforation with a trend for improved survival (HR, 0.67; 95% confidence interval, 0.27-1.05; P = 0.16).
  • Patients with TILs or perforation seemed to gain more survival benefit from chemotherapy (HR, 0.22 and 0.21, respectively) than patients without these features (HR, 0.84 and 0.82, respectively).
  • Because the presence of TILs reflects an adaptive immune response and perforation is associated with inflammatory response, these results suggest that there may be interactions between the immune system and chemotherapy leading to improved survival of colon cancer patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Intestinal Perforation / diagnosis. Lymphocytes, Tumor-Infiltrating / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316563.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Zamir N, Ahmed S, Akhtar J: Mucinous adenocarcinoma of colon. APSP J Case Rep; 2010 Jul;1(2):20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of colon.
  • We report two cases of mucinous adenocarcinoma of colon, one in a 9 years old male and other in a female of 12 years.
  • He had mucinous adenocarcinoma (T3N0MX) of rectosigmoid region and underwent local complete resection of the tumor with colostomy.
  • He also received postoperative chemotherapy and later underwent colostomy reversal.
  • The girl presented with signs of intestinal obstruction and at colonoscopy a stricture found in descending colon.
  • The tumor was resected and biopsy reported as poorly differentiated mucinous adenocarcinoma with positive mesenteric nodes positive for tumor (T3N2MX).
  • She is on chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):218-9 [7527858.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] Indian Pediatr. 2001 Aug;38(8):933-4 [11521016.001]
  • [Cites] Paediatr Drugs. 2008;10(3):177-92 [18454570.001]
  • [Cites] Indian J Cancer. 2008 Jul-Sep;45(3):119-22 [19018116.001]
  • [Cites] Afr J Paediatr Surg. 2009 Jan-Jun;6(1):65-7 [19661674.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Ayub Med Coll Abbottabad. 2007 Jul-Sep;19(3):56-63 [18444593.001]
  • (PMID = 22953263.001).
  • [ISSN] 2218-8185
  • [Journal-full-title] APSP journal of case reports
  • [ISO-abbreviation] APSP J Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Other-IDs] NLM/ PMC3417995
  • [Keywords] NOTNLM ; Bleeding per rectum / Child / Mucinous adenocarcinoma / Colorectum
  •  go-up   go-down


3. Singhal SR, Nanda S, Chaudhry P, Sen J, Singhal SK: Metastatic bilateral malignant ovarian tumors associated with pregnancy. Taiwan J Obstet Gynecol; 2009 Jun;48(2):167-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pregnancy was preserved, and bilateral oophorectomy, omentectomy with resection of sigmoid colon growth, and colostomy were performed.
  • The patient aborted spontaneously and postoperatively, and was treated with adjuvant chemotherapy.
  • CONCLUSION: Because platinum-based chemotherapy can be safely given during pregnancy, hysterectomy can be avoided in cases of bilateral malignant ovarian tumors if the uterus is not grossly involved, so allowing preservation of an existing pregnancy.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / pathology. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic / ultrasonography
  • [MeSH-minor] Abortion, Spontaneous. Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Omentum / surgery. Ovariectomy. Pregnancy. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Taiwan J Obstet Gynecol. 2011 Sep;50(3):405-6; author reply 407 [22030067.001]
  • (PMID = 19574181.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Liberale G, Elias D, Sideris L, Lasser P, Malka D, Sabourin JC, Pocard M: Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy. J Surg Oncol; 2005 Jul 1;91(1):73-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
  • Early postoperative intraperitoneal chemotherapy (EPIC) and intraoperative peritoneal hypertermic chemotherapy (IPHC) are used in addition with cytoreductive surgery to treat with curative intent peritoneal carcinomatosis arising from colorectal adenocarcinomas.
  • Three patients with such a disease were treated with perioperative intraperitoneal chemotherapy in addition to cytoreductive surgery and presented isolated local recurrence located in the inguinal canal (round ligament in two and spermatic cord in one).
  • No patient showed evidence of intra-abdominal recurrence at the last follow-up, but one developed pulmonary metastasis.
  • When communicating with the peritoneal cavity, the inguinal canal may act as a sanctuary site for peritoneal carcinomatosis, since it is not totally soaked by the intraperitoneal chemotherapy solution.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Carcinoma / drug therapy. Colonic Neoplasms / pathology. Inguinal Canal. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / surgery. Cecal Neoplasms / pathology. Cecal Neoplasms / surgery. Colectomy / methods. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Leucovorin / administration & dosage. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999360.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Shih HH, Lu CC, Tiao MM, Ko SF, Chuang JH: Adenocarcinoma of the colon in children presenting as abdominal pain: report of two cases. Chang Gung Med J; 2002 May;25(5):349-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the colon in children presenting as abdominal pain: report of two cases.
  • Adenocarcinoma of the colon is an unusual disease in patients under 30 years of age, and generally presents as advanced disease because of a lack of awareness of its occurrence, especially in the pediatric age group.
  • The authors report on 2 cases of colon cancer in children less than 17 years old, whose initial presentations were abdominal pain of unclear etiology and non-specific abdominal complaints.
  • Barium studies revealed the typical colon lesions in both patients, and colonoscopic pathologic examination disclosed mucinous adenocarcinoma.
  • The therapeutic approach included surgery and adjuvant chemotherapy, but both patients ultimately died due to poor response and early recurrence.
  • Clinical characteristics, diagnosis, and treatment of colon cancer in pediatric patients are discussed.
  • [MeSH-major] Abdominal Pain / etiology. Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12141710.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


6. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • In contrast, solid serous adenocarcinomas, endometrioid adenocarcinomas, and mucinous adenomas expressed GlcNAc6ST-2 much less frequently or not at all.
  • RT-PCR analysis confirmed that GlcNAc6ST-2 transcripts are expressed in ovarian mucinous adenocarcinomas but not in mucinous adenomas.
  • In addition, immunohistochemical analysis using sulfated glycan-specific monoclonal antibodies showed that ovarian adenocarcinoma cells express GlcNAc 6-O-sulfated glycans, including an L-selectin ligand and its related glycans.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):179-87 [10228898.001]
  • [Cites] J Cell Biol. 1999 May 17;145(4):899-910 [10330415.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):193-8 [10188718.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1130-2 [1701274.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):543-9 [10491328.001]
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):711-6 [1720922.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47747-50 [11585845.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11225-33 [9556613.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):38-49 [8423020.001]
  • [Cites] Cell. 2001 Jun 29;105(7):957-69 [11439191.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2127-35 [10232599.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Obstet Gynecol. 1993 Jul;82(1):143-7 [8515915.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] Oncol Res. 1999;11(5):233-41 [10608618.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22577-83 [9712885.001]
  • [Cites] Immunity. 2001 Aug;15(2):237-47 [11520459.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):3979-84 [11726653.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1544-50 [9537262.001]
  • [Cites] Glycobiology. 2002 Jun;12(6):379-88 [12107080.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):285-91 [12619114.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Glycobiology. 2000 Sep;10(9):919-29 [10988253.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):33-5 [8261457.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1057-61 [10339657.001]
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


7. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS, Wegener's Granulomatosis Etanercept Trial Research Group: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum; 2006 May;54(5):1608-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone.
  • This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients.
  • At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded.
  • The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma.
  • There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use.
  • The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization.
  • Patients who developed solid tumors were older than patients who did not.
  • All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial.
  • There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment.
  • CONCLUSION: Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.
  • [MeSH-major] Granulomatosis with Polyangiitis / drug therapy. Immunoglobulin G / adverse effects. Neoplasms / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16646004.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-001652-01; United States / NIAMS NIH HHS / AR / K24-AR-02126-04; United States / NIAMS NIH HHS / AR / K24-AR-049185-01; United States / NIAMS NIH HHS / AR / K24-AR-2224-01A1; United States / NCRR NIH HHS / RR / M01-RR-30; United States / NCRR NIH HHS / RR / M01-RR0-0042; United States / NCRR NIH HHS / RR / M01-RR0-00533; United States / NCRR NIH HHS / RR / M01-RR0-2719; United States / NIAMS NIH HHS / AR / N01-AR-9-2240
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; OP401G7OJC / Etanercept
  •  go-up   go-down


8. Saxena A, Yan TD, Chua TC, Morris DL: Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol; 2010 May;17(5):1291-301
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
  • BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has demonstrated improved survival in selected patients with pseudomyxoma peritonei (PMP).
  • However, this aggressive treatment modality has been consistently associated with variable rates of perioperative mortality between 0% and 18% and morbidity between 30% and 70%.
  • This study evaluates the clinical and treatment-related risk factors for perioperative morbidity and mortality in PMP patients who underwent CRS and PIC.
  • The association of 12 clinical and 20 treatment-related risk factors with grades III and IV/V morbidity were assessed by univariable and multivariable analysis.
  • Eight factors were associated with grade IV/V morbidity on univariable analysis: peritoneal cancer index >or=21 (P = .034), ASA score >or=3 (P = .003), operation duration >or=10 h (P < .001), left upper quadrant peritonectomy procedure (P = .037), colonic resection (P = .012), ostomy (P = .005), ileostomy (P = .012), and transfusion >or=6 units (p = 0.011).
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / mortality. Postoperative Complications / mortality. Pseudomyxoma Peritonei / mortality
  • [MeSH-minor] Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Morbidity. Perioperative Care. Prospective Studies. Risk Assessment. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Jan;18(1):282-3; author reply 284-5 [20645012.001]
  • (PMID = 20039212.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA: VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol; 2008 Mar;15(3):738-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.
  • BACKGROUND: High levels of vascular endothelial growth factor (VEGF) in ovarian cancer metastases are associated with a worse prognosis in patients treated with chemotherapy.
  • VEGF-directed therapy improves survival for those with metastatic colorectal cancer.
  • Patients with mucinous adenocarcinomas metastatic to the peritoneal surfaces can be treated with cytoreductive surgery, and both tumor grade and cytoreduction status are prognostic.
  • We hypothesized that angiogenic indices may be prognostic in patients undergoing cytoreductive surgery for mucinous adenocarcinoma of the appendix and colon.
  • CD 34 counts (blood vessels) and VEGF expression was evaluated by means of immunohistochemistry on specimens from patients undergoing cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP) for mucinous adenocarcinoma.
  • RESULTS: A total of 26 males and 9 females, with a mean age of 50 years, underwent cytoreductive surgery and IPHP for mucinous adenocarcinoma of appendiceal (n = 32) or colonic (n = 3) origin.
  • CONCLUSIONS: These results suggest that markers of tumor angiogenesis may predict survival in patients with peritoneal surface metastases from mucinous adenocarcinoma.
  • These findings provoke the hypothesis that antiangiogenic therapies may be effective in patients with this devastating disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Biomarkers, Tumor / biosynthesis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / therapy. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043973.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


10. Angelopoulos S, Kanellos I, Christophoridis E, Tsachalis T, Kanellou A, Betsis D: Five-year survival after curative resection for adenocarcinoma of the colon. Tech Coloproctol; 2004 Nov;8 Suppl 1:s152-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year survival after curative resection for adenocarcinoma of the colon.
  • BACKGROUND: The purpose of this study was to evaluate the 5-year survival of patients with colon adenocarcinoma that underwent elective or emergency curative surgical treatment.
  • PATIENTS AND METHODS: Between 1993 and 1998, 80 patients underwent a potentially curative colonic resection based on mobilisation along anatomic planes.
  • All patients classified as TNM stage III underwent adjuvant chemotherapy.
  • Patient's sex and age, mucinous characteristics of the tumour and tumour location did not significantly affect survival.
  • CONCLUSIONS: The treatment of colon adenocarcinoma with curative resection by the end of the 20th century is accompanied with acceptable rates of overall 5-year survival.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Colonoscopy. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655605.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Takemura M, Osugi H, Lee S, Kaneko M, Tanaka Y, Fujiwara Y, Nishizawa S, Iwasaki H: [Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1053-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues].
  • 5-FU is the most widely used anticancer drug for digestive system cancers, and it has been recently reported that the effect of 5-FU varies with the amount of enzymes that are involved in the drug metabolism in the cancer tissue.
  • In this report, we measured DPD and OPRT activities in the normal mucosa and colorectal cancer tissues and compared them with clinicopathological factors to examine the choice of chemotherapy for colorectal cancers.
  • Forty-six patients with colorectal carcinoma (28 colon and 18 rectal cancers), which were resected in our department from 1999 to March 2003, were examined.
  • There was no significant difference in the DPD activities between the normal and cancer tissues, whereas OPRT showed significantly higher activity in the cancer tissues.
  • Although we did not find a relation between the DPD activity and clinicopathological factors, the OPRT activity showed a significant difference between gender and classification of tumor, and mucinous adenocarcinoma showed significantly lower OPRT activity than differentiated adenocarcinoma.
  • The DPD activity of mucinous adenocarcinoma is related to catabolism of 5-FU is equal to that of adenocarcinoma, however, the OPRT activity is related to a main pathway of 5-FU phosphorylation is significantly lower.
  • Thus, mucinous adenocarcinoma of the colon was more resistant to 5-FU than the differentiated adenocarcinoma.
  • Therefore, for chemotherapy of mucinous adenocarcinoma, anticancer agents other than 5-FU should be selected.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Dihydrouracil Dehydrogenase (NADP) / metabolism. Fluorouracil / therapeutic use. Orotate Phosphoribosyltransferase / metabolism. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272584.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei arising from colonic polyps.
  • AIMS: Pseudomyxoma peritonei may have as its primary site a mucinous gastrointestinal adenoma or carcinoma that gains access to the peritoneal cavity.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • The patients developed the characteristic pseudomyxoma peritonei syndrome.
  • All three patients were treated with cytoreductive surgery plus perioperative hyperthermic intraperitoneal chemotherapy.
  • CONCLUSIONS: Colonic polyps can serve as a source of dysplastic cells whereby pseudomyxoma peritonei can result.
  • Caution to prevent seeding to the free peritoneal cavity during surgery for colonic polyps should be observed.
  • If pseudomyxoma peritonei develops, cytoreductive surgery and perioperative intraperitoneal chemotherapy should be considered for treatment.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Female. Humans

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Hu JL, Huang JJ, Fu XH: [Survival status and prognostic factors of liver metastases from colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):286-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The median survival time of the 112 patients was 18.25 months.
  • Univariate analysis demonstrated that gender, age, primary tumor site, chemotherapy and pathological types had no significant correlation with the overall survival.
  • But the treatment of primary tumor, time of liver metastasis, gross type of tumor, resection of liver metastases and clinical stage status were all independently related with the prognosis of patients.
  • Multivariate regression analysis showed that resection of liver metastases, gross type of tumor and clinical stage were key factors affecting the prognosis of patients with liver metastases from colorectal cancer.
  • CONCLUSION: Patients with advanced stage, infiltrative gross type of colorectal cancer should be followed-up closely so that liver metastases from the cancer can be diagnosed and treated early.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510081.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, Riggs M, Ward H, Keville L: Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer; 2004 Nov;4(4):262-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival.
  • Monoclonal antibody-directed therapy has been used as an effective treatment for some cancers that overexpress HER2/neu and vascular endothelial growth factor (VEGF).
  • Overexpression of the HER2/neu oncogene and VEGF has been reported to occur in adenocarcinomas of the colon.
  • Assessing whether HER2/neu and VEGF overexpression could serve as prognostic indicators for stage II colon cancer may provide insight into optimal treatment following surgery.
  • Demographic and tumor characteristics from 109 patients diagnosed with stage II colon cancer between 1991 and 1996 were assessed for HER2/neu and VEGF expression using immunohistochemical staining techniques.
  • There was no significant difference in overall survival or in time to recurrence between the groups with and without HER2/neu overexpression.
  • There was a trend toward decreased overall survival with VEGF expression (P = 0.07), but no difference in time to recurrence (P = 0.63).
  • There were 18 patients who received adjuvant chemotherapy, but removal of these patients from the analysis did not change the results.
  • There was no association between HER2/neu and VEGF expression and patient demographics or tumor characteristics, with the exception of VEGF expression and mucinous histology (P < 0.01).
  • Our results do not support an association between HER2/neu or VEGF expression and overall survival or time to recurrence in stage II colon cancer.
  • With further investigation, a significant correlation may be found between VEGF expression and prognosis, and thus direct therapy with a monoclonal antibody.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Receptor, ErbB-2 / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. United States / epidemiology

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15555209.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


15. Oneç B, Oksüzoğlu B, Hatipoğlu HG, Oneç K, Azak A, Zengin N: Cavernous sinus syndrome caused by metastatic colon carcinoma. Clin Colorectal Cancer; 2007 Jul;6(8):593-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous sinus syndrome caused by metastatic colon carcinoma.
  • Cranial metastasis has been reported as infrequent during colon cancers and usually occurs in the late stages with liver and/or lung metastasis.
  • A 34-year-old man underwent a right hemicolectomy for a mucinous adenocarcinoma of the right colon 14 months before presentation.
  • Because metastatic implants on the omentum were detected during the operation, combination chemotherapy was begun.
  • After 5 months of the last cycle of the chemotherapy, his left eyelid began to droop, left eye movements became limited, and he began experiencing numbness of his right forehead and cheek.
  • Despite antiedematous treatment and radiation therapy, he did not experience marked improvement of his symptoms.
  • He could not be given chemotherapy and died 2.5 months after the first symptom of cavernous sinus metastasis.
  • Primary colon adenocarcinoma with cavernous sinus metastasis is very rare.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cavernous Sinus. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681107.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bae JM, Kim SW, Kim SW, Song SK: [Metachronous four primary malignancies in gastro-intestinal tract]. Korean J Gastroenterol; 2009 Jun;53(6):373-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, multiple primary malignancies are considered to increase due to improved survival rate of cancer patients, advanced diagnostic tools, and increased use of chemotherapy and radiotherapy.
  • Recently, we experienced a 70 year-old male who was diagnosed with metachronous four primary malignancies in rectum, ascending colon, stomach, and ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis. Gastrointestinal Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Humans. Male. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556845.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


17. Chen HT, Lee YT, Chou AS, Wu YK, Yin WY, Lee MC, Hsu YH: Primary appendiceal malignancy: a clinicopathologic study. Kaohsiung J Med Sci; 2006 Dec;22(12):618-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were three mucinous adenocarcinomas, two colonic type adenocarcinomas, and three adenocarcinoids.
  • In our series, palliative resection for disseminated lesions with or without additional chemotherapy resulted in long-term survival.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Aged. Cystadenocarcinoma, Mucinous / pathology. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116623.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


18. Tsai HL, Lu CY, Hsieh JS, Wu DC, Jan CM, Chai CY, Chu KS, Chan HM, Wang JY: The prognostic significance of total lymph node harvest in patients with T2-4N0M0 colorectal cancer. J Gastrointest Surg; 2007 May;11(5):660-5
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with radically resected colorectal carcinoma, lymph node involvement is particularly important for a good prognosis and adjuvant therapy.
  • We excluded 186 patients who received postoperative adjuvant chemotherapy via oral or intravenous transmission to prevent possible chemotherapeutic effects on patients' prognosis; therefore, a total of 180 patients with T(2-4)N(0)M(0) colorectal carcinoma were enrolled into this study.
  • The 5-year overall survival rate of T(2-4)N(0)M(0) colorectal carcinoma patients who had 18 or more lymph nodes examined was significantly higher than those who had less than 18 nodes examined (P = 0.015).
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Lymph Node Excision / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Colectomy. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):142-6 [15011850.001]
  • [Cites] Dis Colon Rectum. 1988 Mar;31(3):204-9 [3349876.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):115-22 [3511864.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2):126-8 [8306831.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Gut. 2002 Jul;51(1):65-9 [12077094.001]
  • [Cites] Dis Colon Rectum. 1994 Apr;37(4):373-6; discussion 376-7 [8168417.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1333-6 [11584211.001]
  • [Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):911-8 [11978516.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1753-8 [14534691.001]
  • [Cites] World J Surg. 1999 Jul;23(7):721-6 [10390594.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • (PMID = 17468927.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Spunt SL, Pratt CB, Rao BN, Pritchard M, Jenkins JJ, Hill DA, Cain AM, Pappo AS: Childhood carcinoid tumors: the St Jude Children's Research Hospital experience. J Pediatr Surg; 2000 Sep;35(9):1282-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood carcinoid tumors: the St Jude Children's Research Hospital experience.
  • BACKGROUND/PURPOSE: To better characterize childhood carcinoid tumors, the authors reviewed the clinical presentation, treatment, and outcomes of pediatric patients with these rare tumors.
  • METHODS: A retrospective review was conducted of medical records and pathologic materials of all children with carcinoid tumors treated at St Jude Children's Research Hospital between December 1977 and March 1999.
  • In 7 cases, carcinoid tumor was not suspected at the time the tumor was identified.
  • Seven patients had localized disease; 5 remain disease-free after complete resection, and 2, whose carcinoid tumors were identified incidentally, died of metastatic mucinous adenocarcinoma of the colon.
  • One patient who presented with symptoms of carcinoid syndrome had metastatic disease that responded poorly to cytotoxic chemotherapy and remains alive with active disease.
  • New therapeutic strategies are needed for these patients.
  • [MeSH-minor] Adolescent. Appendectomy. Child. Female. Humans. Male. Pneumonectomy. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10999679.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Kumar S, Wig JD, Kochhar R, Vaiphei K: Concurrent renal transitional cell carcinoma and right colon cancer. Indian J Gastroenterol; 2000 Jan-Mar;19(1):35-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent renal transitional cell carcinoma and right colon cancer.
  • A 45-year-old man who had undergone right radical nephrectomy for transitional cell carcinoma 3 months earlier was admitted with right colonic tumor.
  • Review of CT done for right kidney tumor was suggestive of right colon pathology.
  • Right hemicolectomy was performed, followed by a course of chemotherapy for mucinous adenocarcinoma, and he is well a year later.
  • [MeSH-major] Carcinoma, Transitional Cell. Colonic Neoplasms. Kidney Neoplasms. Neoplasms, Multiple Primary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Humans. Male. Middle Aged. Tomography, X-Ray Computed


21. Bosch Roig CE, Roselló-Sastre E, Alonso Hernández S, Almenar Cubells D, Grau Cardona E, Camarasa Lillo N, Bautista D, Molins Palau C: Prognostic value of the detection of lymph node micrometastases in colon cancer. Clin Transl Oncol; 2008 Sep;10(9):572-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the detection of lymph node micrometastases in colon cancer.
  • INTRODUCTION AND OBJECTIVES: A study is made of the clinical repercussions of occult metastases-micrometastases (MMs+)-or isolated tumour cells (ITCs+) in the lymph nodes of patients with stage IIA and IIB colon adenocarcinoma initially considered as corresponding to N0.
  • MATERIAL AND METHODS: A retrospective study of 39 patients with stage IIA and IIB (T3-T4 N0 M0) colon adenocarcinoma, subjected to similar surgical and adjuvant chemotherapy treatment, with long and careful follow-up (minimum: 5 years, mean: 81.7 months) was performed on their previously resected lymph nodes, with the aid of new histological and immunohistochemical (cytokeratin) sections, in order to detect MMs or ITCs.
  • When comparing the group of MMs+/ITCs+ patients and the group of MM-/ITCs- patients, the DFS and GS times at 5 years were higher in the MMs-/ITCs- group (p=0.0692 and p=0.006 respectively).
  • We encourage a detailed histological study of lymph nodes resected in patients with deep penetrating colon tumours in order to assure a pN0 status.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / blood. Colonic Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratins / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4232-41 [12377967.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2740-1 [14669301.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] J Surg Oncol. 2004 Mar;85(3):166-70 [14991889.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):402-6 [14976530.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):300-4 [11352302.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):917-20 [1717210.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):676-80 [17005470.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] Colorectal Dis. 2003 Mar;5(2):164-8 [12780907.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1244-9 [9788387.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1465-71 [9407986.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] Int J Colorectal Dis. 1998;13(2):99-102 [9638496.001]
  • (PMID = 18796374.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


22. Turrini O, Viret F, Guiramand J, Lelong B, Bège T, Delpero JR: Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol; 2007 Aug;33(6):735-40
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for the treatment of synchronous liver metastasis.
  • Perioperative chemotherapy was considered completed if all expected cycle were administrated.
  • The median survival time of group I-group II were respectively 46 months-40 months (p=0,07).
  • Patients with simultaneous or staged resection receiving optimal treatment (R0 liver surgery and complete chemotherapy) were respectively 89% and 67% (p=0,04).
  • Twenty three patients developed isolated liver recurrence with higher frequency in staged patients (26% vs 9% p=0,03) without impairment of survival.
  • CONCLUSIONS: Because of postoperative morbidity and prolonged tiring treatment, many patients having staged resection were under treated.
  • However we did not observe statistical difference on survival but we supported that simultaneous resection has to be prefer to achieve an optimal treatment.
  • [MeSH-major] Colonic Neoplasms / surgery. Liver Neoplasms / secondary. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Catheter Ablation. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Laparotomy. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400418.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Brunetti G, Delmastro M, Poggi G, Avanza F, Bertoli G: Sudden improvement of respiratory failure in a woman with carcinoma of the colon. Monaldi Arch Chest Dis; 2002 Feb;57(1):35-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden improvement of respiratory failure in a woman with carcinoma of the colon.
  • The patient's lack of consent to laser resection of the mass led to the use of chemotherapy; after the first cycle of treatment a neoplastic mass about 3 cm long was spontaneously expelled with a cough.
  • The expulsion of the metastasis caused rapid improvement of the dyspnea and gas exchange; however, the continuation of the chemotherapy did not bring any further benefit to the patient, who died 115 days after diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174701.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • The medical records were studied to analyze the age, sex, clinical presentation, diagnostic procedures, extent of disease (Dukes staging), treatment, histological types, and outcome.
  • Surgical procedures were done in 11 patients (incomplete resection with segmental resection in 4 patients, complete resection in the other 4, and biopsy alone in 3 patients).The predominant histological type was mucinous carcinoma.
  • Seven patients received adjuvant chemotherapy, all of whom did not survive.
  • Because radical surgery which is the mainstay of treatment is possible only in patients with early stage disease, a high level of awareness and early diagnosis are critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Chemotherapy, Adjuvant. Child. Colonoscopy. Costa Rica / epidemiology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Prognosis. Retrospective Studies. Survival Rate / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Fullerton DA, López F, Avendaño R, Aparicio R, Wistuba I: [Atypical presentation of a colorectal carcinoma]. Rev Med Chil; 2004 Aug;132(8):985-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cáncer colorrectal de presentación atípica.
  • A thorax CAT scan showed a proliferating mass in the splenic angle of the colon, with left lung and diaphragmatic invasion.
  • Endoscopic biopsies confirmed the diagnosis of adenocarcinoma.
  • The pathological report showed a mucosecretory adenocarcinoma, infiltrating the pericolonic adipose tissue without adjacent organ infiltration and a chronic inflammatory process involving colonic serosa, diaphragm pleura, and lung.
  • Adjuvant chemotherapy was indicated and the patient is asymptomatic and without evidences of tumor recurrence after a 24 months follow up.
  • [MeSH-major] Adenocarcinoma, Mucinous. Colorectal Neoplasms. Diaphragm. Lung Neoplasms. Muscle Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15478301.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


26. Shnyder SD, Cooper PA, Pettit GR, Lippert JW 3rd, Bibby MC: Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res; 2003 Mar-Apr;23(2B):1619-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
  • BACKGROUND: The tubulin depolymerizing drug Combretastatin A-1 phosphate (CA1P), a water-soluble derivative of combretastatin A-1, has been recently shown to have a better efficacy in experimental models than the clinically active, close structural analogue, combretastatin A-4 phosphate (CA4P).
  • MATERIALS AND METHODS: In this study the synergistic effects of administering CA1P in combination with cisplatin (CPL) in a well-differentiated transplantable murine colon model (MAC 29) was evaluated.
  • CONCLUSION: These data demonstrate that the combination of CA1P and CPL has significant preclinical antitumour activity against a transplantable murine adenocarcinoma model that is related to the antivascular effects of CA1P.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Angiogenesis Inhibitors / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / pharmacology. Colonic Neoplasms / pathology. Stilbenes / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Drug Screening Assays, Antitumor. Drug Synergism. Female. Mice. Mice, Inbred Strains. Neoplasm Transplantation

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820431.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA44344-07-12
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Stilbenes; 109971-63-3 / combretastatin A-1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Lin L, Xu JM, Wang Y, Ge FJ, Liu LJ, Zhao CH, Li SS, Liu JZ, Li ZQ: [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Oct;32(10):786-90
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
  • OBJECTIVE: To assess the efficacy and safety of bevacizumab plus irinotecan-based regimen for the first line treatment in metastatic colorectal cancer (mCRC) patients, and to investigate the correlation between serum tumor markers including CEA and CA19-9 and response as well as prognosis.
  • METHODS: From May 2007 to July 2008, 67 previously untreated mCRC patients received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22).
  • The treatment continued until disease progression or unacceptable toxicity.
  • Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (χ(2) = 3.42, P = 0.18).
  • The serum CEA and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05).
  • CONCLUSION: The addition of bevacizumab to irinotecan-based regimen significantly improves the response rate and PFS in first-line treatment for patients with mCRC and its toxicity is well tolerated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal, Humanized / therapeutic use. Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Angiogenesis Inhibitors / adverse effects. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Diarrhea / chemically induced. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Hypertension / chemically induced. Leucovorin / therapeutic use. Male. Middle Aged. Neutropenia / chemically induced. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163073.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal, Humanized; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


28. Fang H, Wang XY, Wang JW, Zhang HG, Feng FY, Shi YK: [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):220-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The median survival time of these patients was 19.0 months.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615265.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R: Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Invest; 2002;20(7-8):992-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Mucinous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Diseases / drug therapy. Drug Hypersensitivity / etiology. Fluorouracil / adverse effects. Quinazolines / therapeutic use. Thiophenes / therapeutic use. Thymidylate Synthase / antagonists & inhibitors
  • [MeSH-minor] Aged. Female. Humans. Leucovorin / therapeutic use. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12449732.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Quinazolines; 0 / Thiophenes; EC 2.1.1.45 / Thymidylate Synthase; FCB9EGG971 / raltitrexed; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F: Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine; 2002 Nov 24;20(4):184-90
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Camptothecin / analogs & derivatives. Colorectal Neoplasms / blood. Endothelial Growth Factors / blood. Fibroblast Growth Factor 2 / blood. Intercellular Signaling Peptides and Proteins / blood. Lymphokines / blood. Neoplasm Proteins / blood. Neovascularization, Pathologic / blood. Nitric Oxide / blood
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoembryonic Antigen / analysis. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Colonic Neoplasms / blood. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Life Tables. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Nitrates / blood. Organoplatinum Compounds / administration & dosage. Prognosis. Proportional Hazards Models. Rectal Neoplasms / blood. Rectal Neoplasms / drug therapy. Rectal Neoplasms / mortality. Rectal Neoplasms / surgery. Survival Analysis. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12543084.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / Nitrates; 0 / Organoplatinum Compounds; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 04ZR38536J / oxaliplatin; 103107-01-3 / Fibroblast Growth Factor 2; 31C4KY9ESH / Nitric Oxide; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


31. Malani AK, Olofsson B, Debono D: Remission of hepatic metastasis from colon cancer after methotrexate withdrawal. Am J Med; 2006 Apr;119(4):366-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of hepatic metastasis from colon cancer after methotrexate withdrawal.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Antirheumatic Agents / administration & dosage. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Methotrexate / administration & dosage. T-Lymphocytes, Cytotoxic / drug effects
  • [MeSH-minor] Aged. Arthritis, Rheumatoid / drug therapy. Colectomy. Humans. Lymphocyte Activation. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564789.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement